Healthcare company Ro stated on Wednesday that it will administer the Moderna COVID-19 vaccinations to eligible New Yorkers directly in their homes to help the elderly, disabled and the homebound facing logistical challenges accessing vaccination sites under the COVID-19 Vaccine Drive and in consultation with the New York State's Department of Health.
The company's free COVID-19 Vaccine Drive will be launched this week in select zip codes in Yonkers, New York, initially focusing on seniors 65 years old and older. In-home vaccination appointments can be scheduled at covidvaccinedrive.com by eligible individuals. The second doses for each recipient will be scheduled on site after the first shot and administered in-home as part of the programme. Vaccine recipients can use the hotline for general counselling regarding the vaccine and any potential side effects.
To ensure the COVID-19 Vaccine Drive reaches those with limited digital access or literacy challenges, the partners are working with Yonkers Mayor Mike Spano and Yonkers Office for the Aging to engage relatives and caregivers who can sign up eligible vaccine recipients and help coordinate in-home vaccinations on their behalf. Uber is donating free rides to help cover a portion of the transportation costs.
Upon the initial launch, the company will expand its COVID-19 Vaccine Drive in New York to additional communities. This programme is has received financial support from Firstmark, General Catalyst, TQ Ventures, BoxGroup, 3L Capital, Initialized Capital and Ramp.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Formation Bio acquires worldwide rights to FHND5032 from CTFH
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
Almirall receives China approval for Seysara to treat moderate-to-severe acne